. Yamamoto et al. (9 ) demonstrated that BNP is a more powerful marker of either left ventricular systolic dysfunction, left ventricular diastolic dysfunction, or left ventricular hypertrophy than is ANP or NT-proANP. A consistent finding of all reports is the excellent negative predictive value of BNP. Furthermore, BNP has a good negative likelihood ratio for diagnosis of LVD compared with standard clinical indices, such as clinical history, electrocardiogram, and chest x-ray (17 ) . These clinical results led to the development of numerous commercially available assays to determine different natriuretic peptide hormones (18 ) . However, different epitopes and fragments of the same analyte are detected by different assays, and cross-reactivities of antibodies with prohormone fragments may vary. Because natriuretic peptide assays are not standardized at present, clinical study results must be interpreted with caution when different assays are used.
The aims of this study were (a) to investigate which of the natriuretic peptides, BNP, NT-proBNP, or NTproANP, performs best in the diagnosis of mild forms of LVD and (b) to investigate the impact of using different assays on the diagnostic performance of these natriuretic peptides.
Materials and Methods patients
We investigated 130 consecutive patients (median age, 63.5 years; age range, 28 -83 years) with clinically suspected mild LVD, which could be caused by either isolated diastolic or systolic LVD. Patients were classified according to the NYHA classification (19 ) and according to the recommendations of the task force of the American College of Cardiology and the American Heart Association (four stages) (20 ) . All patients were referred for routine coronary angiography between December 2000 and January 2001 to rule out substantial coronary artery disease. Patients gave written informed consent for blood sampling for natriuretic peptide measurements, and this study is consistent with the Declaration of Helsinki. All patients underwent left heart catheterization with left ventriculography. Additionally, a complete echocardiographic examination assessed all clinically relevant routine indices such as left ventricular ejection fraction (LVEF), regional systolic left ventricular function, diastolic function, left ventricular mass, and systolic pulmonary artery pressure. These examinations were performed by experienced cardiologists who were blinded to the natriuretic peptide results. Isolated diastolic LVD was defined according to the guidelines of the European Society of Cardiology (21 ) as an age-adjusted pathologic mitral valve diastolic inflow pattern on Doppler echocardiography together with an increased left ventricular end-diastolic pressure Ն16 mmHg in the presence of a normal LVEF (Ͼ50% in two-dimensional echocardiography). This precluded misclassification based on higher age alone. All patients with diastolic dysfunction showed the pattern of impaired relaxation in echocardiography. Systolic dysfunction was graded by use of the echocardiographically determined LVEF. Patients were grouped into three classes based on the following criteria: mild systolic LVD was defined as a LVEF of 40 -50% on two-dimensional echocardiography, moderate LVD was defined as a LVEF of 30 -40% on echocardiography; and severe LVD was defined as a LVEF Ͻ30%. Forty-seven patients with neither systolic nor diastolic LVD served as age-and sex-matched controls.
For the clinical study on the diagnostic performance of markers in suspected mild LVD, 44 patients were excluded for the following reasons: 6 patients had moderate to severe LVD; 31 patients had a myocardial infarction within 2 weeks of blood withdrawal; 5 patients presented with renal diseases; and 2 patients underwent a high-dose corticosteroid pretreatment for contrast-agent allergy. The final study population for this clinical investigation comprised 86 individuals (Table 1 ). All patients of this population had calculated systolic right ventricular pressures (by echocardiography) within the reference interval (Ͻ35 mmHg) and no evidence of right ventricular dysfunction on echocardiography. However, samples from all 130 patients were used for testing assay agreement of the different natriuretic peptides.
Blood was drawn into EDTA-containing plastic tubes after a standardized period of rest (10 min) in a supine position. After blood withdrawal, samples were stored at 4°C (up to 1 h) until measurement of BNP in whole blood (Triage BNP); subsequently samples were centrifuged at 2000g for 10 min at 4°C, and the plasma was stored below Ϫ20°C for up to 1 month for later determination of BNP, NT-proBNP, and NT-proANP by the different assays. The study design was prospective with respect to measurement of BNP, NT-proBNP, and NT-proANP for the clinical evaluation of the diagnostic performances of these different natriuretic peptides and retrospective with respect to the measurement of these peptides with different assays for assay comparison. Because of limited sample volumes, not every sample could be tested with all assays (see the Results). All patient samples were analyzed with the Triage BNP, Biomedica NT-proBNP, and Biomedica NT-proANP assays; subsequently, if the sample volume was sufficient, samples were analyzed with the Roche NT-proBNP and finally with the Shionoria BNP assay.
assays BNP was measured with the Triage BNP Test (Biosite Diagnostics) as described previously (22 ) . This assay uses a murine Omniclonal antibody bound to the fluorescent label and a murine monoclonal antibody against the mono-disulfide bond-mediated ring structure of BNP-32. This monoclonal antibody is bound to the solid phase (personal communication by the manufacturer).
In addition, BNP was measured by a commercially available IRMA (cat. no. IC-1049; Shionoria), which does not need plasma extraction procedures as described preClinical Chemistry 50, No. 7, 2004 viously (23 ) . The assay uses an antibody specific to the C-terminal structure (amino acids 27-32) immobilized on a bead and a 125 I-labeled antibody specific to the intramolecular ring structure of human BNP-32 (amino acids 14 -21), respectively (24 ) .
NT-proBNP (8 -29) was assayed by a competitive enzyme immunoassay (cat. no. BI-20852; Biomedica) that uses an antibody specific against NT-proBNP(8 -29) as described previously (25 ) .
Additionally, NT-proBNP(1-76) was measured by a sandwich electrochemiluminescence immunoassay (Elecsys 1010; Roche Diagnostics) that uses polyclonal antibodies specific against the epitopes NT-proBNP(1-21) and NT-proBNP(39 -50) as described previously (26, 27 ) .
NT-proANP(1-98) was measured by a sandwich enzyme immunoassay (cat. no BI-20892; Biomedica), which uses antibodies specific for distinct epitopes of proANP(1-98), as described previously (28 ) .
coronary angiography and left ventriculography
Coronary angiography and left ventriculography were performed via femoral artery access using the Seldinger puncture technique. A 6-French pigtail catheter was used 23 (49) 8 (40) 6 (32) 1-Vessel disease, n (%)
14 (30) 5 (25) 7 (37) 2-Vessel disease, n (%)
8 (17) 3 (15) 1 (5) 
2 (4) 4 (20) 5 (26) History of AMI, n (%)
10 (21) 7 (35) 12 (63) 1 vs 3: P ϭ 0.001 Diabetes mellitus type 2, n (%)
5 (11) 1 (5) to measure left ventricular end-diastolic and end-systolic filling pressures, and the first derivative of left ventricular pressure (dP/dt). The ventriculogram was analyzed by use of a computer software package. Calculation of the end-diastolic and end-systolic left ventricular volumes and ejection fraction was performed by use of the right anterior oblique projection by the area-length method.
The frame nearest to the R-wave peak in the electrocardiogram was used as the end-diastolic frame, and the frame with the smallest ventricular volume was taken to calculate the end-systolic volume. Left ventricular volumes were normalized to body surface area.
Coronary angiography was performed according to the Judgkin technique. The degree of stenosis of coronary vessels was assessed visually in several projections by an experienced invasive cardiologist. Stenosis Ͼ70% of the vessel diameter was classified as hemodynamically significant.
echocardiography
Each patient underwent a complete standardized echocardiographic examination using an Acuson ultrasound imaging system (Acuson Sequoia C256; Siemens) equipped with a 3.5-MHz transducer suitable for second harmonic imaging. Parasternal long-and short-axis views as well as four, two, and three long-axis chamber views were obtained. Left ventricular volumes and ejection fraction were measured from the two-dimensional apical fourchamber view by the area-length method (modified Simpson method). The end-diastolic thicknesses of the intraventricular septum and the left ventricular posterior wall were measured in a parasternal short-axis view using the M-mode technique, and the Penn formula was used to calculate left ventricular mass. Left ventricular mass and volumes were normalized to body surface area. Left ventricular diastolic filling was evaluated by pulsed-wave Doppler measurement of velocities of early and late ventricular diastolic filling (E-and A-wave), as well as the deceleration time of the E-wave. Right 
Results

natriuretic peptide concentrations
BNP, NT-proBNP, and NT-proANP increased significantly with the clinical severity of HF symptoms (Table 2) Fig. 1, A and B) . Additionally, in patients with isolated diastolic LVD Triage BNP concentrations [37 (22-81 ) ng/L; P ϭ 0.018; Fig. 1A ] showed significant increases compared with controls. By contrast, NT-proANP concentrations were not significantly increased in either patients with mild LVD or patients with isolated diastolic LVD (Fig. 1C) .
comparison of markers
Mild systolic LVD. In patients with mild systolic LVD, the Triage BNP and Biomedica NT-proBNP showed comparable diagnostic performances (Fig. 2 ) with mean [95% at optimal cutoff values (see Fig. 2 ) were 90 (76 -97)% for BNP, 83 (67-94)% for NT-proBNP, and 77 (61-88)% for NT-proANP, respectively.
Isolated diastolic LVD.
In patients with isolated diastolic LVD, the mean (95% CI) AUC for the Triage BNP (Fig. 3 ) of 0.70 (0.56 -0.81) showed significantly better (P ϭ 0.006) diagnostic performance than the AUC for the Biomedica NT-proBNP [0.49 (0.34 -0.65)]. At the optimal cutoff value of 25 ng/L for Triage BNP, the sensitivity was 70 (46 -88)%, the specificity was 57 (42-72)%, the positive predictive value was 41 (25-59)%, the negative predictive value was 82 (65-93)%, and the efficiency was 61 (49 -73)%. NT-proANP had a smaller mean AUC of 0.63 (0.48 -0.76), but was not significantly different from the Triage BNP.
correlations of natriuretic peptides with each other and with hemodynamic data
We found close correlations between the Triage BNP and Roche NT-proBNP (r ϭ 0.88; P Ͻ0.001), between the Shionoria BNP and Biomedica NT-proBNP (r ϭ 0.82; P Ͻ0.001), and between the Shionoria BNP and Roche NT-proBNP (r ϭ 0.88; P Ͻ0.001). The Triage BNP and Biomedica NT-proBNP correlated as well (r ϭ 0.78; P Ͻ0.001). Correlations between NT-proANP and the other natriuretic peptides were weak (r ϭ 0.34 -0.51; P Ͻ0.001). There were only weak correlations between natriuretic peptides and myocardial mass, atrial and ventricular dimensions, or hemodynamic data (r ϭ Ϫ0.052 to 0.337; P Ͻ0.001-0.96). The closest correlations were between the natriuretic peptides and LVEF obtained from left ventriculography (Triage BNP, r ϭ Ϫ0.459; Biomedica NTproBNP, r ϭ Ϫ0.376; P Ͻ0.001).
comparison of assays BNP. In 81 individuals, the Triage BNP and Shionoria BNP assays showed a close correlation (r ϭ 0.96; P Ͻ0.01). Nevertheless, absolute BNP values measured with both assays differed markedly (P Ͻ0.001), with concentrations measured by the Triage BNP being, on average, 110 ng/L higher (mean value of difference). However, there was better agreement of test results below concentrations of 100 ng/L (mean value of difference, 9.2 ng/L; Fig. 4A ).
NT-proBNP.
In 113 individuals, the NT-proBNP(8 -29) assay (Biomedica) showed a moderate correlation with the NT-proBNP(1-76) assay (Roche; r ϭ 0.73; P Ͻ0.01). These assays also showed a marked concentration difference (see Fig. 4B ) with a mean difference of 1803 ng/L (P Ͻ0.001).
influence of measuring with different assays on the diagnostic performance of bnp and NTproBNP
In a subgroup analysis, we compared the diagnostic performance of the Triage BNP and Shionoria BNP assays. There was equal diagnostic performance for both assays [mean (95% CI) AUC, 0.68 (0.49 -0.84) for Triage BNP and 0.74 (0.56 -0.88) for Shionoria; P ϭ 0.09; for the diagnosis of mild systolic LVD. In a further subgroup analysis, the diagnostic performance of the Biomedica and Roche NT-proBNP was compared. There was no statistically significant impact of assays on the ability of NT-proBNP to differentiate between controls and patients with mild systolic LVD (Table 4) . However, in the comparison of the diagnostic performances of NT-proBNP in patients with isolated diastolic LVD, the diagnostic performance of the Biomedica NT-proBNP assay was significantly worse compared with the Roche NT-proBNP assay [P ϭ 0.03; mean (95% CI) AUC, 0.44 (0.29 -0.59) vs 0.58 (0.42-0.73); Table 4 ].
Discussion
In the present study, in contrast to several earlier published studies, we used a very exact definition of mild systolic LVD and isolated diastolic LVD based on several objective measurements (19 -21 ) . Our controls were matched for age and sex and were very well characterized, showing normal echocardiographic, left ventriculographic, and left ventricular hemodynamic results. In agreement with our previous study (8 ) , BNP and NTproBNP were interchangeable as diagnostic markers in patients with mild systolic LVD, whereas the diagnostic performance of NT-proANP was significantly worse than that of BNP. BNP and NT-proBNP concentrations were significantly increased in patients with mild systolic LVD compared with controls, independent of the assay used. In contrast, NT-proANP concentrations did not differ significantly from concentrations in controls. The lack of a significant increase in NT-proANP in mild systolic LVD is in contrast to some previous reports (13, 15, 16 ) . One explanation for this discrepancy is that there was less severe impairment of LVEF in our patients with systolic LVD. In the present study, the grading of the severity of LVD was not based solely on subjective individual symptoms, where LVEF can vary considerably in patients of a given NYHA class; objective data obtained from echocardiography and cardiac catheterization were also used to classify the severity of LVD. Furthermore, measurement of natriuretic peptide by less precise RIAs, which require extraction of plasma samples, may have influenced the results of earlier studies. However, our results agree very well with previous studies showing good performance of BNP and NT-proBNP compared with other natriuretic peptides or their second messenger, cGMP, in patients with impaired LVEF (8, 9, 11, 12, 31, 32 ) . In contrast to the results reported by Prontera et al. (33 ) , in our study the diagnostic performance of BNP and NT-proBNP was comparable. However, Prontera et al. could not exclude whether the differences in marker performance were just an effect of differences in assay precision. Our results showing the high negative predictive values of BNP and NT-proBNP confirmed results obtained in previous studies and indicate that these markers may be suitable tools to rule out mild systolic LVD in high-risk patients.
Using the European Society of Cardiology classifica- Concentrations were log-transformed to exclude relationships between difference and magnitude and to achieve a gaussian distribution of values. tion of isolated diastolic dysfunction based on echocardiographic and hemodynamic data, we confirmed the significant increase in BNP, as measured by the Triage BNP assay, reported previously by Lubien et al. (34 ) , who used only echocardiographic criteria. However, we did not observe a similarly high diagnostic performance of Triage BNP, which may be explained by the fact that our cohort did not include patients with restrictive filling patterns. The high negative predictive value of BNP (82%) in the present study confirms the results of a previous report (35 ) and underlines the accuracy of BNP as a rule-out marker even for isolated diastolic LVD. Thus, BNP is a promising marker for the diagnosis of isolated diastolic LVD as well. We found no significant difference in the diagnostic performance of BNP and NT-proANP for the diagnosis of isolated diastolic LVD, which confirms a previous report of increased ANP and BNP concentrations in diastolic LVD (36 ) . We found significant correlations among all tested natriuretic peptides. In accordance with previous studies, we found only weak inverse correlations of LVEF and BNP (7-9, 12, 37 ) . There are only two published studies (in which LVEF was determined by magnetic resonance imaging) showing a close correlation between BNP and LVEF (r ϭ Ϫ0.78) (38 ) and between NT-proBNP (Roche) and LVEF (r ϭ Ϫ0.75) (39 ) in patients in NYHA classes II-IV. The more severely reduced LVEF than in our study population and the more precise method for the calculation of LVEF likely account for the closer correlations.
There was a close correlation between BNP measured by Biosite Triage and by Shionoria assay. However, Bland-Altman plots showed an acceptable agreement between methods only at concentrations Ͻ100 ng/L. There was no influence of the BNP assay used on the diagnostic performance of the marker. By contrast, the correlation between NT-proBNP measured by the Biomedica and Roche methods was only moderate, and Bland-Altman plots revealed only poor test agreement over the whole measuring range. Nevertheless, NTproBNP assays were not significantly different in identifying patients with mild systolic LVD. However, in patients with isolated diastolic LVD, the AUC were significantly different. The epitopes detected by the different assay antibodies in the NT-proBNP molecule are different, which may influence diagnostic endpoints in very mild forms of LVD.
There are very limited data on the influence of measuring natriuretic peptides with different assays on diagnostic performance. In accordance with our results, Tjeerdsma et al. (40 ) and Fischer et al. (22 ) found a close correlation between Triage BNP and Shionoria BNP results, with Triage BNP values being higher than Shionoria values. However, the AUC for the assays were higher in both studies compared with our AUC for BNP, which can be explained in part by either the more severely diseased patient cohort or by a younger control group not agematched to the LVD patient group. Our data confirm the lack of influence of the assay used on the diagnostic performance of BNP in less severe LVD. Data regarding the recently Food and Drug Administration-cleared Centaur (Bayer) BNP assay showed a high correlation with the Shionoria as well as with the Triage BNP assays in a large multisite study (24 ) . The close correlation with the Shionoria assay is not surprising because the antibodies are identical in both assays (24 ) . However, the slope of 0.78 between the Centaur (Bayer) and the Triage (Biosite) BNP assays showed that these assays did not agree very well. Nevertheless, similar to our results, there was a high agreement at a cutoff value of 100 ng/L. For the Roche and Biomedica methods, a recent report demonstrated a similar lack of assay and analytical agreement with a large mean concentration difference between the NT-proBNP assays similar to that seen in our study (41 ) .
Our results for differentiating patients with isolated diastolic LVD from controls showed better performance of the Roche assay compared with the Biomedica assay, similar to that seen in the previous study for differentiating patients with asymptomatic structural heart disease (42 ) . Close correlations between all assays were found, but data on analytical assay agreement were not published. We found higher diagnostic efficiency of BNP and NT-proBNP than did the authors of that study (42 ), although we included only patients with mild forms of LVD who consequently had lower BNP and NT-proBNP concentrations.
In conclusion, our study confirms the usefulness of BNP and NT-proBNP and extends previous findings by directly comparing commercially available BNP and NTproBNP assays in the same study population. Furthermore, our results highlight the diversity of the natriuretic peptide assays on the market. Thus it is difficult to compare study results that are based on different assays. Published decision limits are valid only for the particular assay used. Our study population was too small for additional subgroup analysis to calculate age-and sexdependent decision limits, but from our results a cutoff of 50 ng/L (14 pmol/L) for the Triage BNP assay could be a good screening value to exclude LVD in high-risk patients.
The BNP Triage tests and NT-proBNP Elecsys assays were gifts from Biosite (Velizy, France) and Roche (Penzberg, Germany), respectively. BNP Shionoria assays were a gift from Bayer Diagnostics (Tarrytown, NY), and NTproANP and NT-proBNP assays were partly provided free of charge from Biomedica (Vienna, Austria). The assay manufacturers had no influence on the study design, data analysis or interpretation, or the content of this report.
